// App-Quantinova.ai

2956 : SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Researchers

Presenter

  • Dagmar Hess

Principal Investigators

  • Thomas Pabst

  • Marianne Kraus

  • Sarah R Haile

  • Markus Joerger

  • Roger von Moos

  • Catherine Berset

  • Susanne Crowe

  • Hilde Rosing

  • Hermen S Overkleeft

  • Christiana Sessa

Medical Centers

  • Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland

  • Institute of Medical Oncology, Bern University Hospital, Bern, Switzerland

  • Cantonal hospital of Graubunden, Chur, Switzerland

  • Slotervaart Hospital, Amsterdam, Netherlands

  • Oncology/Hematology, Cantonal Hospital, St. Gallen, Switzerland

  • Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland

  • Department of Oncology, Kantonsspital, St Gallen, Switzerland

Locations

  • Switzerland

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Hematological malignancies

  • Pulmonary embolism

  • Multiple Myeloma

  • Thrombocytopenia

  • B cell lymphomas

  • Dyslipidemia

  • Neutropenia

  • Venous thrombosis

  • Lymphomas

Biomarkers

  • Alanine transaminase

  • Peripheral blood mononuclear cell

  • Phosphorylated-AKT

Drug/Treatment

  • Lenalidomide

  • Bortezomib

  • Nelfinavir mesylate

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved